Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cll1 car-t + cd33 car-t
- Development stage
- Unknown
- Lead developer
- General Hospital of Western Theater Command of PLA
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CLL1 CAR-T + CD33 CAR-T is an investigational dual-targeting chimeric antigen receptor T-cell (CAR-T) therapy developed for the treatment of relapsed or refractory acute myeloid leukemia (AML). This cell-based immunotherapy involves engineering patient-derived T cells to express chimeric antigen receptors directed against two distinct AML-associated surface antigens: CLL1 (C-type lectin-like molecule-1, also known as CLEC12A), which is expressed on leukemic stem cells, and CD33, which is broadly expressed on AML blast cells. By simultaneously targeting both antigens, the therapy aims to eliminate bulk AML disease and eradicate leukemic stem cells while reducing the risk of antigen-escape relapse that can occur with single-target CAR-T approaches. It is currently being evaluated in clinical trials sponsored by The General Hospital of Western Theater Command in China.
- Other names
- CLL1/CD33 CAR-TCLL1/+CD33 CAR-T
02
Targets
CLEC12ACD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on cll1 car-t + cd33 car-t.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cll1 car-t + cd33 car-t.